Drug Profile
Research programme: hepatitis B virus gene antagonists - Sangamo Therapeutics
Alternative Names: Hepatitis B zinc finger protein transcription factors research programme - SangamoLatest Information Update: 11 Jan 2017
Price :
$50
*
At a glance
- Originator Sangamo BioSciences
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
- 20 Aug 2001 This programme is still in active development
- 29 May 2001 Sangamo BioSciences is preparing several candidate proteins for animal studies